Articles On Starpharma Holdings (ASX:SPL)

29 Aug 2019 - Starpharma (ASX:SPL) has seen positive results with targeted DEO using antibody fragment in human ovarian cancer model.

The Avita Medical Ltd (ASX: AVH) share price has risen more than 500% since January. This may lead to some investors avoiding Avita Medical shares in fear of paying too much. However, even after this massive price rise, I believe the share...

The Starpharma Holdings Limited (ASX: SPL) share price has been amongst the best performers on the All Ordinaries index on Wednesday. In morning trade the dendrimer products developer’s shares raced as much as 6% higher to $1.21 following...

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

The Australian health system is tagged amongst the best in the world and focusses on providing safe and affordable health care for all the Australians. The federal, state and local government jointly run the system to ensure its adherence....

August 2019 is proving to be much more than just a reporting season. Along with the earning releases and outlook notifications, the companies have been hinting towards the various feathers in their caps. Amid these announcements came an upd...

The PolyNovo Ltd (ASX: PNV) share price was amongst the best performers on the All Ordinaries index on Thursday. The medical device company’s shares were up over 10% at one stage before ending the day 9% higher at $1.60. Why did the PolyNo...

Shares in Immuron took a 17 per cent hit this morning after the company revealed its IMM-124E drug did not work in a trial with patients suffering from severe alcoholic hepatitis. Immuron (ASX:IMM), which is developing oral drugs for gut di...

The Starpharma Ltd  (ASX: SPL) share price has jumped 8% higher in early trade after the company provided an update on its phase 1/2 clinical trial for its colorectal cancer drug, DEP irinotecan. What did Starpharma say in its latest updat...

The Starpharma Holdings Limited (ASX: SPL) share price rose 3% after giving its June 2019 trading update. Starpharma describes itself as a world leader in the development of dendrimer enhanced products (DEP) for pharmaceutical, life science...

This morning healthcare business Starpharma Ltd (ASX: SPL) reported a net investing and operating cash outflow for the quarter ending June 30 2019 on revenue of $626,000. For the full financial year it reported an investing and operating c...

I have recently spent some time reviewing the annual reports and announcements from S&P/ASX 200 (INDEXASX: XJO) index-listed company, Starpharma Holdings Limited (ASX: SPL) to assess the merit of buying SPL shares. Starpharma shares la...

The Starpharma Holdings Limited (ASX: SPL) share price has been a positive performer again on Thursday. In afternoon trade the dendrimer products developer’s shares have stormed almost 5% higher to $1.44. Why is the Starpharma share price...

The S&P/ASX 200 index is fighting hard to keep its head above water on Thursday. In afternoon trade the benchmark index is up slightly to 6,643.5 points. Four shares that have climbed more than most today are listed below. Here’s why t...

Super Retail Group Limited, Domain Holdings Australia Limited, Metcash Limited and Starpharma Holdings Limited have depicted a similar upward trend in generating a good YTD return. Let us have a view on the recent updates of these players l...

Australian company Starpharma (ASX:SPL) has announced a new development and option agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product version of one of the UK company's oncology medicines.